Syndax Pharmaceuticals Profit Margin 2015-2021 | SNDX
Current and historical gross margin, operating margin and net profit margin for Syndax Pharmaceuticals (SNDX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Syndax Pharmaceuticals net profit margin as of June 30, 2021 is -6031.18%.
|Syndax Pharmaceuticals Annual Profit Margins
|Syndax Pharmaceuticals Quarterly Profit Margins
||Medical - Biomedical and Genetics
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.